The Insider: Investors Edition - Quarter 3: 2024 | Venture Partners at ��ƷSM��ӰƬ

The Insider: Investors Edition - Quarter 3: 2024

��ƷSM��ӰƬ Startups in the News

Aerial photo of the ��ƷSM��ӰƬ campus with the Boulder Flatirons in the background.

2024 cohort of ��ƷSM��ӰƬ’s Embark Deep Tech Startup Creator launches new startups

The Embark Deep Tech Startup Creator pairs seasoned entrepreneurs with university technologies to bring those breakthroughs to market in response to urgent societal needs. Embark has launched its second Entrepreneurs in Residence cohort and will provide Intellectual Property rights, salary support, grant funds and investor introductions to launch startups with real-world impact.

Activate announces founders of ��ƷSM��ӰƬ spinouts in Cohort 2024

Activate is a nonprofit organization that empowers scientists to transform their research into market-ready products and services through a two-year fellowship that provides funding, mentorship and access to a robust network of experts and resources. Three Cohort 2024 fellows join Activate from companies spun up at ��ƷSM��ӰƬ with Venture Partners at ��ƷSM��ӰƬ.

If GPS goes dark, Mesa Quantum has a backup plan

CNBC—��ƷSM��ӰƬ startup Mesa Quantum has raised $3.7 million in seed funding on top of a $1.7 million Space Force grant to develop chip-scale quantum sensors.
The startup’s quantum sensors could bring navigation, timing and positioning data to electronic devices of every kind, alleviating their need to pick up distant GPS satellite signals. Many GPS satellites covering the U.S. have aged beyond their initially intended lifespan.

Illustration of ones and zeros superimposed on an atom-like illustration of spirals

Boulder quantum firm Infleqtion, a CU spinout, raises nearly $11M

BizWest—Infleqtion, a quantum information company that began as ColdQuanta at ��ƷSM��ӰƬ, raised about $10.8 million from investors this month, according to a pair of Form Ds filed recently with the U.S. Securities and Exchange Commission. The fundraiser came less than two months after the company hired Matthew Kinsella as its new CEO.

Think Bioscience, a ��ƷSM��ӰƬ spinout, raises $26M to find ‘pockets’ for drug therapies

BizWest—Think Bioscience, a ��ƷSM��ӰƬ spinout, has raised a $26 million seed round—including a recently completed $6 million expansion of the initial fundraise—to develop small-molecule therapeutics that target “undruggable” proteins.

OnKure, a ��ƷSM��ӰƬ spinout, hitches Reneo's ride to Nasdaq in merger, with $65M PIPE to boot

Fierce Biotech—OnKure Therapeutics, a ��ƷSM��ӰƬ spinout, has merged with Reneo Pharmaceuticals, jumping onto Wall Street with $120 million and a lead breast cancer treatment challenging the likes of Eli Lilly, Relay and Scorpion. The merged biotech will retain OnKure's name and is set to trade under the ticker “OKUR.”

Investment Opportunities: ��ƷSM��ӰƬ Startups Seeking Funding

Arpeggio develops more effective and safer medicines by designing molecules that target not a single protein but the entire cellular network.

Funding Sought: $20 million Series A Extension
For information: Joey Azofeifa, joey@arpeggiobio.com

Aspero Medical's differentiated products improve endoscopy while providing financial incentives for providers, improving patient outcomes and reducing the total cost of care.

Funding Sought: $5 million Series A
For information: Mark Rentschler mark.rentschler@asperomedical.com

Darwin specializes in saliva-based diagnostics for the early detection of infectious diseases by translating signals in human saliva derived from the earliest immune response using a portable, hand-held device.

Funding Sought: $25 million Series A
For information: Nick Myerson, nick@darwin.bio

Illumen Therapeutics

Illumen Therapeutics is pursuing a cancer treatment moonshot, developing PARN Inhibitor drugs to increase functional p53, the 'Guardian of the Genome,' to treat aggressive cancers.

Funding Sought: $5 million Pre-Seed
For information: Bob Blomquist, bob@IllumenTx.com

Think Bioscience's unique approach to drug discovery combines applied microbiology, enzymology and computational science to develop small-molecule therapeutics against elusive targets.

Funding Sought: $50 million Series A (opening early 2025)
For information: Philip Jeng, pjeng@thinkbioscience.com

TissueForm aims to improve life for people affected by joint cartilage disease or damage by harnessing the natural, restorative power of tissue extracellular matrix.

Funding Sought: $2 million Seed (opening early 2025)
For information: Jeanne Barthold,

��ƷSM��ӰƬ Startup Pipeline News

Scenic view of the ��ƷSM��ӰƬ campus with red-roofed buildings surrounded by autumn trees in vibrant shades of yellow and orange. The famous Flatirons mountains loom in the background under a bright blue sky with scattered white clouds.

Venture Partners Update: Startups Surge

By translating breakthrough research into new businesses, CU creates economic opportunities while addressing many of the world’s greatest challenges. In the past year, ��ƷSM��ӰƬ has burned especially bright through Venture Partners’ record-setting performance.

A group of predominantly white men stand at a ribbon cutting in the entrance of a laboratory

��ƷSM��ӰƬ, Elevate Quantum partners ready for $127M regional quantum boost

��ƷSM��ӰƬ Today—Elevate Quantum, of which ��ƷSM��ӰƬ is a key partner, announced today that it has received a Tech Hub Phase 2 implementation award from the Department of Commerce, unlocking more than $127 million in new federal and state funding.

Gov. Jared Polis signs quantum industry bill on ��ƷSM��ӰƬ campus

��ƷSM��ӰƬ Today—Colorado Gov. Jared Polis ushered in a new bill to support the state’s rapidly growing quantum industry. Polis signed the bill from the top floor of the JILA Tower, one of the epicenters of quantum research on campus, with a view of the Flatirons in the background.

Life-sciences leaders: Pfizer’s exit means opportunity

BizWest—Leaders of Boulder's and the university's life-sciences community who gathered at the BioFrontiers Institute at ��ƷSM��ӰƬ for a BizWest CEO Roundtable said they saw Pfizer’s recent departure as a lucrative opportunity.

��ƷSM��ӰƬ

For University Innovators

For Investors & Partners

Opportunities & Events

Newsroom

For University Innovators

For Investors & Partners

Opportunities & Events

Newsroom

Search

Other ways to search: